Progression Therapeutics

Progression Therapeutics is a biotechnology company dedicated to discovering and developing novel therapies that target the fundamental drivers of cancer progression. The company utilizes a proprietary platform to identify specific molecular changes that occur as tumors transition from indolent to aggressive states. Founded by Dr. David Agus and Dr. Parag Mallick, the firm leverages proteomics and advanced data analytics to pinpoint high-value targets that are essential for tumor evolution and metastasis. Their lead programs focus on small molecule inhibitors designed to halt disease progression and overcome treatment resistance in various solid tumors. Progression Therapeutics is backed by prominent venture capital firms and operates primarily in the pre-clinical research phase.